Bernard Francq

Dr. Bernard Francq

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2019 in Statistics in Medicine
Verified
Journal Article
Open access
PDF file
BFBernard Francq
Bernard Francq
DLDan Lin
Dan Lin
WHWalter Hoyer
Walter Hoyer
The literature about Prediction Interval (PI) and Tolerance Interval (TI) in linear mixed models is usually developed for specific designs, which is a main limitation to their use. This paper proposes to reformulate the two‐sided PI to be generalizable under a wide variety of designs (one random factor, nested and crossed designs for multiple random factors, and balanced or unbalanced designs). This new methodology is based on the Hessian matrix, namely, the inverse of (observed) Fisher Information matrix, and is built with a cell mean model. The degrees of freedom for the total variance are calculated with the generalized Satterthwaite method and compared to the Kenward‐Roger's degrees of freedom for fixed effects. Construction of two‐sided TIs are also detailed with one random factor, and two nested and two crossed random variables. An extensive simulation study is carried out to compare the widths and coverage probabilities of Confidence Intervals (CI), PIs, and TIs to their nominal levels. It shows excellent coverage whatever the design and the sample size are. Finally, these CIs, PIs, and TIs are applied to two real data sets: one from orthopedic surgery study (intralesional resection risk) and the other from assay validation study during vaccine development.


23 September 2020 in Statistics in Medicine
Verified
Journal Article
Open access
PDF file
BFBernard Francq
Bernard Francq
MBMarion Berger
Marion Berger
CBCharles Boachie
Charles Boachie
The well‐known agreement interval by Bland and Altman is extensively applied in method comparison studies. Two clinical measurement methods are considered interchangeable if their differences are not clinically significant. The agreement interval is commonly applied to assess the spread of the differences. However, this interval is approximate (too narrow) and several authors propose calculating a confidence interval around each bound. This article demonstrates that this approach is misleading, awkward, and confusing. On the other hand, tolerance intervals are exact and can include a confidence level if needed. Tolerance intervals are also easier to calculate and to interpret. Real data sets are used to illustrate the tolerance intervals with the R package BivRegBLS under normal or log‐normal assumptions. Furthermore, it is also explained how to assess the coverage probabilities of the tolerance intervals with simulations.

13 June 2025 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
DSDaniel Skomski
Daniel Skomski
AJAndrea Ji
Andrea Ji
DKDrago Kuzman
Drago Kuzman
DCDidier Clenet
Didier Clenet
AHAaron Hieb
Aaron Hieb
DLDeclan Lowney
Declan Lowney
The perspective review discusses predictive stability computational modeling and scientific risk-based approaches to prospectively assess long-term stability and shelf-life of biotherapeutics and vaccines. New regulatory approaches are considered in the context of evolving industry guidelines which are expected to lead to increased usage in clinical trials and market applications. Case studies for many critical quality attributes are broadly covered. Model methodologies, complexities, and mitigations, as well as emerging technologies, are also explained. Outputs of an industry-wide survey elucidate how biopharmaceutical companies are navigating this changing environment. Altogether, it is suggested that predictive stability holds promise for accelerating patient access to new medicines by overcoming stability-related bottlenecks while further enhancing scientific understanding and product robustness.


18 January 2025 in Communications Medicine
Verified
Journal Article
Open access
PDF file
FMFrédéric Mathot
Frédéric Mathot
ELEdwige Lefebvre
Edwige Lefebvre
BFBernard Francq
Bernard Francq
DGDelphine Guillaume
Delphine Guillaume
EBErwan Bourles
Erwan Bourles
Background The adenovirus-vaccine platform has come to prominence with the COVID-19 vaccination campaigns. The objective of this study was to validate a formulation that was suitable for lyophilisation and long-term storage at 5 (2–8) °C. Methods Vaccine stability was assessed up to five years at 5 °C using a lyophilised formulation of the chimpanzee-adenovirus vector ChAd155 encoding a respiratory syncytial virus (RSV) antigen. Vaccine potency was assessed by functional infectivity assay. Other assessments of vaccine stability included those for capsid integrity, particle content, and DNA release. Vaccine efficacy and safety were assessed after two years in a murine model of RSV challenge and a rabbit toxicology model, respectively. Results Here, we show that the potency loss from lyophilisation was 0.12 log10. The potency loss over five years at 5 °C was estimated at 0.21 log10 (95%CI 0.10–0.30). This coincides with a 25% increase in the ratio of non-infectious particles/infectious particles. After two years of storage at 5 °C, (i) the loss of infectivity was 0.17 log10; (ii) the vaccine remained immunogenic and effective at clearing RSV from the lungs in a mouse-challenge model; and (iii) the vaccine was not associated with any adverse safety signal in a rabbit toxicology model. Conclusions The 5-year stability of the lyophilised adenovirus-vector vaccine is within our acceptable limit ( < 0.3 log10 decrease). Its formulation process is amenable to manufacturing scale-up and should help in providing adenovirus-based vaccines where the cold chain is problematic, such as in low-income countries, and in pre-epidemic stockpiling.